Shingles Pain That Won’t Stop? Understanding Postherpetic Neuralgia

For most people, shingles is a miserable few weeks and then it’s over. But for a significant minority, the rash heals and the pain doesn’t — it settles into a persistent, often severe nerve pain that can last months or years. This is postherpetic neuralgia (PHN), one of the most common and most distressing forms of neuropathic pain. This article explains why a childhood chickenpox virus can come back decades later to injure nerves, what makes the pain persist, how it is treated, and how it can be prevented.

A virus that never left

Shingles is caused by the varicella-zoster virus (VZV) — the same virus that causes chickenpox. After a childhood chickenpox infection, the virus is not eliminated. It retreats into the dorsal root ganglia, the clusters of sensory nerve cell bodies that sit alongside the spinal cord, and lies dormant there, sometimes for decades, held in check by the immune system.

When immunity wanes — with age, illness, stress, or immune-suppressing conditions and treatments — the virus can reactivate. It travels back down the sensory nerve to the skin, producing the characteristic painful, blistering rash of shingles in a band along the territory of that nerve. But the damage isn’t only skin-deep: the reactivation inflames and injures the nerve and its ganglion along the way.

Why the pain persists: postherpetic neuralgia

In postherpetic neuralgia, the nerve injury from the shingles episode leaves the affected sensory pathway damaged and dysregulated. The injured nerves become hyperexcitable and misfire, and the pain-processing system itself can become sensitized, so that even light touch on the healed skin triggers severe pain (a phenomenon called allodynia). The result is persistent burning, stabbing, or electric pain in the area where the rash was, often accompanied by exquisite sensitivity.

Several factors raise the risk of PHN, most notably older age — the risk climbs substantially with each decade — along with greater severity of the initial shingles episode. This is why prevention and early treatment matter so much.

Treating postherpetic neuralgia

PHN is challenging, but there are real tools, and they work best in combination and tailored to the individual.

Early antiviral treatment of the acute shingles episode (started promptly, within the first days of the rash) can reduce the severity and duration of the outbreak and may lower the risk of persistent pain — one reason to seek care quickly when shingles appears.

For established PHN, treatments include topical therapies — notably the high-concentration 8% capsaicin patch, which is FDA-approved for postherpetic neuralgia and works by quieting the overactive pain fibers in the affected skin (discussed in detail in the capsaicin article), and lidocaine patches — as well as oral neuropathic-pain medications such as gabapentinoids and certain antidepressants. Because PHN is often localized, the topical, non-systemic options are especially valuable for avoiding whole-body side effects.

Beyond symptom control, a repair-and-support philosophy addresses the injured nerve terrain itself. The video notes the use of measures aimed at supporting recovery, including cannabinoid-based therapies and glutathione. In the interest of accuracy: cannabinoids have a growing but still-evolving evidence base for neuropathic pain, and glutathione support for nerve recovery is biologically rational but not a proven cure — both belong in the category of adjuncts used within an individualized, physician-guided plan rather than established standalone treatments.

Prevention: the most important tool

The single most effective way to deal with postherpetic neuralgia is to prevent the shingles episode that causes it. The recombinant shingles vaccine (Shingrix) is highly effective at preventing shingles and, by extension, PHN, and is recommended for older adults and certain immunocompromised individuals. For anyone in an at-risk group who has not been vaccinated, this is a conversation worth having with a physician — preventing the outbreak is far easier than treating the pain it can leave behind.

Where this fits

Postherpetic neuralgia is one of the infection-related drivers of neuropathic pain. Unlike the diffuse, length-dependent neuropathies of metabolic disease, it is typically localized to the nerve territory affected by the shingles outbreak — a distinct pattern that helps identify it and shapes the localized, terrain-supportive approach to treatment.

Frequently asked questions

Key takeaways

• Shingles comes from varicella-zoster virus reactivating from the dorsal root ganglia, injuring the nerve.
• Postherpetic neuralgia is the persistent nerve pain that can follow, driven by nerve damage and sensitization.
• Risk rises sharply with age and with a severe initial outbreak.
• Treatment combines topical options (including the FDA-approved 8% capsaicin patch), oral medications, and terrain support; cannabinoids and glutathione are adjuncts, not proven cures.
• The shingles vaccine is the most effective way to prevent PHN.

Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. 2014;371:1526–1533.
2. Gershon AA, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015.
3. Backonja M, et al. NGX-4010 (capsaicin 8% patch) for postherpetic neuralgia: randomized studies. Lancet Neurol. 2008.
4. Dooling KL, et al. Recommendations of the ACIP for use of recombinant zoster vaccine (Shingrix). MMWR. 2018.